PDCD1 and telomere syndrome: In the anti-PD-1/anti-PD-L1-treated cohorts (GSE78220, GSE93157, IMvigor210), STS patients in the HPSG had a significant survival prognosis, and the response rates in the HPSG and LPSG were 79% versus 23%, 34% versus 24%, 25% versus 13%, indicating that STS patients in the HPSG had better clinical benefits and were more suited to immunotherapy (Fig. 7B–D).